Tradestie Institutional Equity Comparison Engine

ZBIO vs OCUL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while OCUL counters with relative strength in Growth & Margin. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus OCUL at N/M Forward P/E and -680.9% operating margin (-11.5% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against OCUL sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ZBIO N/M vs OCUL N/M Fwd P/E
Growth & Margin Winner OCUL
Op Margin -2747.5% vs -680.9% ยท YoY -100.0% vs -11.5%
Momentum & Technical Winner ZBIO
1Y -21.7% vs -46.3% ยท 52W Pos 46% vs 1%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs BREAKDOWN (7th %ile IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
OCUL NASDAQ
Ocular Therapeutix, Inc.
Pharmaceutical Preparations
$6.01
-3.22% 1D
Market Cap $1.4B
1M Return -12.52%
1Y Return -46.29%
Forward P/E N/M
Unified AI Score
45.2 / 100 HOLD
Tech 19.0 Fund 47.0 Flow 69.0 Mom 64.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% OCUL -46.29% Spread: +24.61 pp (ZBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ZBIO Revenue OCUL Revenue ZBIO Op. Margin OCUL Op. Margin Margin Edge
FY2018 N/A $0M N/A -2970.8% OCUL
FY2019 N/A $0M N/A -2029.9% OCUL
FY2020 N/A $20M N/A -361.1% OCUL
FY2021 N/A $40M N/A -179.3% OCUL
FY2022 N/A $50M N/A -152.7% OCUL
FY2023 $50M $60M -74.3% -141.0% ZBIO
FY2024 $10M $60M -3277.8% -269.6% OCUL
FY2025 $10M $50M -3830.6% -519.8% OCUL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (4) vs OCUL (3)
Institutional Metric ZBIO OCUL Criterion Row Winner
Market Capitalization Scale $1.9B $1.4B Larger Scale ZBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% -11.5% Higher Growth OCUL
Operating Margin (TTM) Profitability -2747.5% -680.9% Higher Margin OCUL
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -265.1% -93.5% Higher ROE OCUL
52-Week Range Position Momentum 46% ($14โ€“$45) 1% ($6โ€“$16) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 1.69ฮฒ ยท 68% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs OCUL Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OCUL BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live OCUL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor OCUL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.